EGFR-IN-206

EGFR-IN-206 (Compound 9f) potently inhibits the proliferation of three EGFR triple-mutant cancer cell lines, including Baf3-EGFR^{L858R/C797S/T790M} (IC₅₀ = 33.3 nM), Baf3-EGFR^{Del19/C797S/T790M} (IC₅₀ = 35.8 nM) and H1975-EGFR^{L858R/C797S/T790M} (IC₅₀ = 95.3 nM)^[1].
EGFR-IN-206 (10-50 nM, 24 h) inhibits the migration and invasion of Baf3-EGFR^{L858R/C797S/T790M} cells and H1975-EGFR^{L858R/C797S/T790M} cells^[1].
EGFR-IN-206 (50-500 nM) increases the proportion of dead cells in H1975-EGFR^{L858R/C797S/T790M} 3D spheroids in a dose-dependent manner^[1].
EGFR-IN-206 (10-1000 nM) reduces the mitochondrial membrane potential of Baf3-EGFR^{L858R/C797S/T790M} and H1975-EGFR^{L858R/C797S/T790M} cells in a dose-dependent manner, promotes cell apoptosis, and increases intracellular reactive oxygen species levels^[1].
EGFR-IN-206 (10-1000 nM) dose-dependently inhibits the phosphorylation of EGFR in H1975-L858R/C797S/T790M cells without altering the expression level of total EGFR^[1].
EGFR-IN-206 inhibits NO secretion in Raw264.7 and THP-1 cells stimulated by LPS (HY-D1056), with EC₅₀ values of 101.4 nM and 144.7 nM, respectively^[1].
EGFR-IN-206 (10-50 nM; 12 h) significantly reduces IL-6 secretion levels in LPS-stimulated Raw264.7 and THP-1 cells after 12 h of incubation^[1].
EGFR-IN-206 (50-100 nM) inhibits the inflammation-enhanced colony-forming ability of H1975-L858R/C797S/T790M cells and reduces IL-6 secretion in the THP-1 co-culture model at a concentration of 50 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.